Seeking Alpha
More on ACAD by Mike Havrilla
Latest ACAD Transcript
-
ACADIA Pharmaceuticals, Inc. Q3 2009 Earnings Conference Call
November 9, 2009
Latest ACAD Articles
-
11 Ache-Free Investment Opportunities in Neuropathic Pain
September 30, 2009 • Michael Becker
-
Take Advantage of Biovail Weakness - RBC
September 2, 2009 • FP Trading Desk
-
Biovail Makes Good on Promise to Transform into Niche Player in CNS Diseases
August 24, 2009 • EP Vantage
-
Extreme FDA Trades: 30 Stocks Under 5 Bucks
August 2, 2009 • Mike Havrilla
-
Monday Options Recap
July 27, 2009 • Frederic Ruffy
-
FDA Calendar: 2H09 Binary Event Trades
July 27, 2009 • Mike Havrilla
-
Extreme FDA Trades: Another 18 Stocks Under 5 Bucks
July 5, 2009 • Mike Havrilla
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
-
Instablogged Stocks
Stocks that instabloggers have most recently written about -
Latest Instablog Posts
-
1
Nine Tech Stocks With Good Cash Utilization ...
-
2
How badly has the debt crisis damaged the re...
-
3
World Markets Brief 12/22: Illiquidity, Mult...
-
4
Prime Mortgage Delinquencies Up 100%+
-
5
New Process Makes Titanium Mining Greener, a...
-
1
-
Top Instabloggers
See all Top Instabloggers » Top StockTalkers »
Acadia Pharmaceuticals Inc. (ACAD)
Posts on ACAD by Mike Havrilla
Extreme FDA Calendar Trades: 18 Stocks Under $5
BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS
Acadia Pharmaceuticals' Cash and Publicity Infusion Make It Attractive
Posts on ACAD by other instabloggers
-
September 29, 2009
•
Michael Becker
-
September 01, 2009
•
BioPharma Investor
-
August 25, 2009
•
Finance Banter
-
July 27, 2009
•
Small Cap Network
-
May 04, 2009
•
MyHappyTrading.com
All instablog posts on ACAD »Ache-free Investment Opportunities in Neuropathic Pain
Acadia Pharmaceuticals: High Risk-Low Reward
Finance Banter Freebies for Tuesday, August 25th - Bob Byrne
Pharmaceuticals Acadia (ACAD), Cerus (CERS) and Vical (VICL) Post Gains and Big Volumes on Hopes of Late Stage Clinical Trial Results
Possible Short-Squeeze Candidates